GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tilray Brands Inc (NAS:TLRY) » Definitions » Beneish M-Score

Tilray Brands (Tilray Brands) Beneish M-Score : -2.73 (As of Apr. 26, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Tilray Brands Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.73 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Tilray Brands's Beneish M-Score or its related term are showing as below:

TLRY' s Beneish M-Score Range Over the Past 10 Years
Min: -3.05   Med: -1.75   Max: 104.82
Current: -2.73

During the past 12 years, the highest Beneish M-Score of Tilray Brands was 104.82. The lowest was -3.05. And the median was -1.75.


Tilray Brands Beneish M-Score Historical Data

The historical data trend for Tilray Brands's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tilray Brands Beneish M-Score Chart

Tilray Brands Annual Data
Trend Aug14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.63 -1.80 -1.75 -2.35 -3.00

Tilray Brands Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.46 -3.00 -3.05 -2.70 -2.73

Competitive Comparison of Tilray Brands's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Tilray Brands's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tilray Brands's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tilray Brands's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Tilray Brands's Beneish M-Score falls into.



Tilray Brands Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Tilray Brands for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9169+0.528 * 0.4375+0.404 * 0.9734+0.892 * 1.2465+0.115 * 1.4353
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8501+4.679 * -0.040261-0.327 * 0.9123
=-2.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Feb24) TTM:Last Year (Feb23) TTM:
Total Receivables was $89.5 Mil.
Revenue was 188.34 + 193.771 + 176.949 + 184.188 = $743.2 Mil.
Gross Profit was 49.396 + 47.409 + 44.196 + 67.163 = $208.2 Mil.
Total Current Assets was $631.2 Mil.
Total Assets was $4,212.9 Mil.
Property, Plant and Equipment(Net PPE) was $596.2 Mil.
Depreciation, Depletion and Amortization(DDA) was $124.2 Mil.
Selling, General, & Admin. Expense(SGA) was $241.8 Mil.
Total Current Liabilities was $329.1 Mil.
Long-Term Debt & Capital Lease Obligation was $365.5 Mil.
Net Income was -92.701 + -49.008 + -71.525 + -138.713 = $-351.9 Mil.
Non Operating Income was -65.966 + -6.247 + -4.749 + -87.358 = $-164.3 Mil.
Cash Flow from Operations was -15.361 + -30.409 + -15.842 + 43.598 = $-18.0 Mil.
Total Receivables was $78.3 Mil.
Revenue was 145.589 + 144.136 + 153.211 + 153.325 = $596.3 Mil.
Gross Profit was -11.699 + 42.882 + 48.614 + -6.733 = $73.1 Mil.
Total Current Assets was $758.5 Mil.
Total Assets was $4,375.9 Mil.
Property, Plant and Equipment(Net PPE) was $431.8 Mil.
Depreciation, Depletion and Amortization(DDA) was $141.9 Mil.
Selling, General, & Admin. Expense(SGA) was $228.2 Mil.
Total Current Liabilities was $469.7 Mil.
Long-Term Debt & Capital Lease Obligation was $321.1 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(89.542 / 743.248) / (78.342 / 596.261)
=0.120474 / 0.131389
=0.9169

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(73.064 / 596.261) / (208.164 / 743.248)
=0.122537 / 0.280073
=0.4375

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (631.211 + 596.236) / 4212.856) / (1 - (758.512 + 431.755) / 4375.9)
=0.708643 / 0.727995
=0.9734

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=743.248 / 596.261
=1.2465

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(141.924 / (141.924 + 431.755)) / (124.176 / (124.176 + 596.236))
=0.247393 / 0.172368
=1.4353

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(241.805 / 743.248) / (228.181 / 596.261)
=0.325336 / 0.382686
=0.8501

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((365.463 + 329.1) / 4212.856) / ((321.104 + 469.682) / 4375.9)
=0.164867 / 0.180714
=0.9123

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-351.947 - -164.32 - -18.014) / 4212.856
=-0.040261

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Tilray Brands has a M-score of -2.73 suggests that the company is unlikely to be a manipulator.


Tilray Brands Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Tilray Brands's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Tilray Brands (Tilray Brands) Business Description

Address
265 Talbot Street West, Leamington, ON, CAN, N8H 5L4
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. U.S. exposure consists of CBD products and alcohol.
Executives
Denise M Faltischek officer: Chief Strategy Officer C/O THE HAIN CELESTIAL GROUP, INC., 1111 MARCUS AVENUE, LAKE SUCCESS NY 11042
Mitchell Gendel officer: Global General Counsel EMERALD HOLDING, INC., 100 BROADWAY, 14TH FLOOR, NEW YORK NY 10005
Irwin D Simon director, officer: President & CEO C/O THE HAIN CELESTIAL GROUP INC., 1111 MARCUS AVENUE, LAKE SUCCESS NY 11042
Carl A Merton officer: Chief Financial Officer C/O TILRAY, INC., 745 FIFTH AVENUE, SUITE 1602, NEW YORK NY 10151
Brendan Kennedy director 1920 EASTLAKE AVENUE E., SEATTLE WA 98105
James R. Meiers officer: Head of Canada C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
David G. Hopkinson director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
Thomas P. Looney director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
Johann Michael Herhalt director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
Jodi L. Butts director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
David F Clanachan director TIM HORTONS INC., 874 SINCLAIR ROAD, OAKVILLE A6 L6K 2Y1
Renah Persofsky director 55 PRINCE ARTHUR AVENUE, #604, TORONTO A6 M5R 1B3
Jon Edward Levin officer: Chief Operating Officer 2701 EASTLAKE AVE E, 3RD FLOOR, SEATTLE WA 98102
Michael C. Kruteck officer: Chief Financial Officer 2701 EASTLAKE AVE E, 3RD FLOOR, SEATTLE WA 98102
Rebekah Dopp director 444 LENOX AVENUE, SOUTH ORANGE NJ 07079